DIA's 8th Middle East Regulatory Conference To Focus On Improved Access To Medicines And Therapies

Main Category: Pharma Industry / Biotech Industry
Article Date: 21 Nov 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The Drug Information Association (DIA), the premier, multidisciplinary, non-profit association that provides a neutral forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes, will host the 8th Middle East Regulatory Conference (20-21 January 2009; Manama, Bahrain).

Key stakeholders, including representatives from ministries of health, local and multinational pharmaceutical companies will exchange views, discuss topics of interest, and identify actions to increase patient access to new and improved medicines and therapies in the Middle East. Sessions topics include:

- Local regulatory authority views and key issues
- Pharmacovigilance
- Pharmacoeconomics
- Counterfeits
- Innovation in the quality arena
- Quality-by-design
- Good Manufacturing Practices including PIC/S
- Biologics
- Evolving global legislation on medicines
- Biosimilars
- Common Technical Document and electronic submissions therapies

"Since its inception 13 years ago, the Middle East Regulatory Conference has grown to become an important forum for discussion of matters related to the provision of healthcare in the region, with a specific focus on issues around the evaluation and supervision of innovative medicines for human use," says Programme Chair Professor Trevor Jones CBE,WHO Commissioner, CIPIH, UK.

This is the 8th DIA Middle East Regulatory Conference in partnership with the Middle East Regulatory Network (MERN). The MERN is an ad hoc regional network of the EFPIA (European Federation of Pharmaceutical Industries and Associations). The MERN works in partnership with regulatory authorities and the pharmaceutical industry in the Middle East to develop legislation and regulatory practices that enable patients to have access to good quality medicines, including innovative medicines.

About the Drug Information Association (DIA)

DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA (USA), and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team.

Drug Information Association